Form 4: BioXcel Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, was granted stock options to purchase 1,875 shares of common stock on July 22, 2024.
Summary
- Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, Inc., was granted stock options on July 22, 2024.
- The options allow him to purchase 1,875 shares of common stock at an exercise price of $1.2.
- The options vest in two equal installments, with 50% vesting on each of the first and second anniversaries of the grant date, contingent upon continuous employment.
- The options expire on July 22, 2034.
- The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025, whereby every sixteen shares were combined into one.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The reverse stock split is a neutral event.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron routinely use stock options to incentivize their leadership teams.
- The vesting schedule of 50% on each of the first and second anniversaries is fairly standard.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Scientific Officer to drive company growth.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 07/22/2024 | Date of stock option grant |
| 02/07/2025 | Effective date of reverse stock split (16:1) |
| 04/01/2025 | Date of Form 4 signature |
| 07/22/2034 | Expiration date of stock options |
Keywords
stock options, BioXcel Therapeutics, executive compensation, Form 4, BTAI, Frank Yocca, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.